PACIRA BIOSCIENCES INC (PCRX) Fundamental Analysis & Valuation

NASDAQ:PCRX • US6951271005

Current stock price

24.51 USD
-0.85 (-3.35%)
At close:
24.41 USD
-0.1 (-0.41%)
Pre-Market:

This PCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. PCRX Profitability Analysis

1.1 Basic Checks

  • In the past year PCRX was profitable.
  • PCRX had a positive operating cash flow in the past year.
  • PCRX had positive earnings in 4 of the past 5 years.
  • PCRX had a positive operating cash flow in each of the past 5 years.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • The Return On Assets of PCRX (0.56%) is better than 80.10% of its industry peers.
  • PCRX has a better Return On Equity (1.01%) than 81.68% of its industry peers.
  • With an excellent Return On Invested Capital value of 2.67%, PCRX belongs to the best of the industry, outperforming 80.63% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for PCRX is significantly below the industry average of 13.10%.
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROIC 2.67%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 0.97%, PCRX belongs to the top of the industry, outperforming 80.10% of the companies in the same industry.
  • PCRX's Profit Margin has declined in the last couple of years.
  • With a decent Operating Margin value of 5.33%, PCRX is doing good in the industry, outperforming 79.58% of the companies in the same industry.
  • PCRX's Operating Margin has declined in the last couple of years.
  • Looking at the Gross Margin, with a value of 79.39%, PCRX belongs to the top of the industry, outperforming 84.82% of the companies in the same industry.
  • PCRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PCRX Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
  • The number of shares outstanding for PCRX has been reduced compared to 1 year ago.
  • The number of shares outstanding for PCRX has been reduced compared to 5 years ago.
  • PCRX has a better debt/assets ratio than last year.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 1.90 indicates that PCRX is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PCRX's Altman-Z score of 1.90 is in line compared to the rest of the industry. PCRX outperforms 57.59% of its industry peers.
  • The Debt to FCF ratio of PCRX is 2.72, which is a good value as it means it would take PCRX, 2.72 years of fcf income to pay off all of its debts.
  • PCRX has a better Debt to FCF ratio (2.72) than 92.15% of its industry peers.
  • A Debt/Equity ratio of 0.54 indicates that PCRX is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.54, PCRX is doing worse than 67.54% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Altman-Z 1.9
ROIC/WACC0.31
WACC8.64%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.54 indicates that PCRX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 4.54, PCRX is in the better half of the industry, outperforming 61.78% of the companies in the same industry.
  • PCRX has a Quick Ratio of 3.28. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of PCRX (3.28) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.28
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PCRX Growth Analysis

3.1 Past

  • The earnings per share for PCRX have decreased strongly by -18.07% in the last year.
  • Measured over the past 5 years, PCRX shows a small growth in Earnings Per Share. The EPS has been growing by 3.64% on average per year.
  • The Revenue for PCRX has decreased by -16.32% in the past year. This is quite bad
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.08% on average per year.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%

3.2 Future

  • Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.54% on average per year.
  • The Revenue is expected to grow by 5.02% on average over the next years.
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.54%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.02%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

8

4. PCRX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 9.32, which indicates a very decent valuation of PCRX.
  • Based on the Price/Earnings ratio, PCRX is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of PCRX to the average of the S&P500 Index (27.42), we can say PCRX is valued rather cheaply.
  • A Price/Forward Earnings ratio of 9.07 indicates a reasonable valuation of PCRX.
  • Based on the Price/Forward Earnings ratio, PCRX is valued cheaply inside the industry as 89.53% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of PCRX to the average of the S&P500 Index (22.29), we can say PCRX is valued rather cheaply.
Industry RankSector Rank
PE 9.32
Fwd PE 9.07
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 91.62% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, PCRX is valued cheaper than 96.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.26
EV/EBITDA 8.06
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PCRX does not grow enough to justify the current Price/Earnings ratio.
  • PCRX has a very decent profitability rating, which may justify a higher PE ratio.
  • PCRX's earnings are expected to grow with 20.27% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.45
PEG (5Y)2.56
EPS Next 2Y16.4%
EPS Next 3Y20.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCRX Dividend Analysis

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCRX Fundamentals: All Metrics, Ratios and Statistics

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (4/24/2026, 8:01:36 PM)

Premarket: 24.41 -0.1 (-0.41%)

24.51

-0.85 (-3.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)04-30
Inst Owners119.39%
Inst Owner Change-0.19%
Ins Owners2.16%
Ins Owner Change16.51%
Market Cap992.41M
Revenue(TTM)726.41M
Net Income(TTM)7.03M
Analysts76.92
Price Target29.29 (19.5%)
Short Float %20.59%
Short Ratio10.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.46%
Min EPS beat(2)-38.21%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)-7.2%
Min EPS beat(4)-38.21%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)1.27%
EPS beat(12)7
Avg EPS beat(12)-1.33%
EPS beat(16)7
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-3.7%
Max Revenue beat(2)-3.59%
Revenue beat(4)0
Avg Revenue beat(4)-4.05%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-2.99%
Revenue beat(8)1
Avg Revenue beat(8)-2.33%
Revenue beat(12)1
Avg Revenue beat(12)-2.76%
Revenue beat(16)1
Avg Revenue beat(16)-2.75%
PT rev (1m)-3.37%
PT rev (3m)-3.37%
EPS NQ rev (1m)-3.67%
EPS NQ rev (3m)-22.96%
EPS NY rev (1m)-11.96%
EPS NY rev (3m)-22.29%
Revenue NQ rev (1m)-0.61%
Revenue NQ rev (3m)-6.62%
Revenue NY rev (1m)-0.29%
Revenue NY rev (3m)-3.76%
Valuation
Industry RankSector Rank
PE 9.32
Fwd PE 9.07
P/S 1.37
P/FCF 7.26
P/OCF 6.53
P/B 1.43
P/tB 3.26
EV/EBITDA 8.06
EPS(TTM)2.63
EY10.73%
EPS(NY)2.7
Fwd EY11.02%
FCF(TTM)3.38
FCFY13.77%
OCF(TTM)3.75
OCFY15.32%
SpS17.94
BVpS17.12
TBVpS7.53
PEG (NY)3.45
PEG (5Y)2.56
Graham Number31.8271 (29.85%)
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROCE 3.38%
ROIC 2.67%
ROICexc 3.38%
ROICexgc 5.91%
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
FCFM 18.81%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
ROICexc(3y)6.66%
ROICexc(5y)7.23%
ROICexgc(3y)14.37%
ROICexgc(5y)26.99%
ROCE(3y)5.91%
ROCE(5y)6.18%
ROICexgc growth 3Y-17.07%
ROICexgc growth 5Y-17.82%
ROICexc growth 3Y-9.16%
ROICexc growth 5Y-18.82%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Debt/EBITDA 2.87
Cap/Depr 16.85%
Cap/Sales 2.11%
Interest Coverage 2.54
Cash Conversion 117.14%
Profit Quality 1942.86%
Current Ratio 4.54
Quick Ratio 3.28
Altman-Z 1.9
F-Score8
WACC8.64%
ROIC/WACC0.31
Cap/Depr(3y)16.8%
Cap/Depr(5y)48.87%
Cap/Sales(3y)1.96%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y2.7%
EPS Next 2Y16.4%
EPS Next 3Y20.27%
EPS Next 5Y10.54%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
Revenue Next Year4.19%
Revenue Next 2Y6.34%
Revenue Next 3Y8.72%
Revenue Next 5Y5.02%
EBIT growth 1Y-65.3%
EBIT growth 3Y-18.29%
EBIT growth 5Y-8.56%
EBIT Next Year0.28%
EBIT Next 3Y34.34%
EBIT Next 5Y7.61%
FCF growth 1Y-23.55%
FCF growth 3Y5.86%
FCF growth 5Y28.37%
OCF growth 1Y-19.75%
OCF growth 3Y1.51%
OCF growth 5Y14.57%

PACIRA BIOSCIENCES INC / PCRX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


Can you provide the valuation status for PACIRA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


Can you provide the profitability details for PACIRA BIOSCIENCES INC?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.


What is the financial health of PACIRA BIOSCIENCES INC (PCRX) stock?

The financial health rating of PACIRA BIOSCIENCES INC (PCRX) is 7 / 10.